A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP (NCT06920004)
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (4 items).
Location: University of Alabama — Birmingham, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
- Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- Use of other long-acting immunomodulatory treatment
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (89 Sites)
- University of Alabama — Birmingham, Alabama
- Samir Macwan, M.D., Inc. — Rancho Mirage, California
- Colorado Springs Neurological Associates — Colorado Springs, Colorado
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Homestead Associates in Research Inc — Homestead, Florida
- Visionary Investigators Network — Miami, Florida
- University of South Florida — Tampa, Florida
- Paradigm Health System — Slidell, Louisiana
- Erlanger Health System — Columbia, Maryland
- University of Michigan Hospital — Ann Arbor, Michigan
- Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Jefferson Health Honickman Center — Philadelphia, Pennsylvania
- NeuroCarePlus — Houston, Texas
- National Neuromuscular Research Institute — Irving, Texas
- INECO Neurociencias Oroño — Rosario,
- Universitätsklinikum AKH Wien — Vienna,
- PSEG Centro de Pesquisa Clinica — São Paulo,
- Hospital Universitario San Ignacio — Bogotá,
- Hospital Alma Máter de Antioquia — Medellín,
- Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico — Medellín,
- Fakultni nemocnice Brno — Brno,
- Astra Kliinik — Tallinn,
- Tartu University Hospital — Tartu,
- AP-HP - Hôpital de la Pitié Salpétrière — Paris, Paris
- CHU de Bordeaux - Hôpital Pellegrin — Bordeaux,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.